Which has higher valuation and earnings, ANL or RANI?

Rani Therapeutics has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 73.92 -$35.53M N/A N/A Rani Therapeutics $1.63M 48.08 -$29.67M -$0.41 N/A

Is ANL or RANI more profitable?

Adlai Nortye's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Rani Therapeutics N/A -206.46% -83.95%

Does the media favor ANL or RANI?

In the previous week, Rani Therapeutics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.93 beat Rani Therapeutics' score of 0.69 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FENC or RANI?

In the previous week, Rani Therapeutics had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Rani Therapeutics and 3 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that Adherex Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LXEO or RANI more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Rani Therapeutics N/A -206.46% -83.95%

Is RANI or ABEO more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Abeona Therapeutics N/A -53.98% -38.52%

Does the media refer more to RANI or ABEO?

In the previous week, Abeona Therapeutics had 10 more articles in the media than Rani Therapeutics. MarketBeat recorded 15 mentions for Abeona Therapeutics and 5 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.69 beat Abeona Therapeutics' score of 0.33 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or RANI more profitable?

Palisade Bio's return on equity of -36.79% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer PALI or RANI?

In the previous week, Palisade Bio had 22 more articles in the media than Rani Therapeutics. MarketBeat recorded 27 mentions for Palisade Bio and 5 mentions for Rani Therapeutics. Palisade Bio's average media sentiment score of 0.92 beat Rani Therapeutics' score of 0.69 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rani Therapeutics (RANI) Competitors

$0.63 -0.05 (-7.95%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$0.64 +0.00 (+0.70%)

As of 07:57 AM Eastern

Compare

RANI vs. ANL, FENC, LXEO, ABEO, and PALI

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include Adlai Nortye (ANL), Adherex Technologies (FENC), Lexeo Therapeutics (LXEO), Abeona Therapeutics (ABEO), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry.

How does Rani Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Rani Therapeutics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.93 beat Rani Therapeutics' score of 0.69 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	73.92	-$35.53M	N/A	N/A
Rani Therapeutics	$1.63M	48.08	-$29.67M	-$0.41	N/A

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 162.45%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,283.18%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Adlai Nortye's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Adlai Nortye beats Rani Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Rani Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Adherex Technologies has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, Rani Therapeutics had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Rani Therapeutics and 3 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Rani Therapeutics	N/A	-206.46%	-83.95%

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adherex Technologies presently has a consensus price target of $15.40, suggesting a potential upside of 43.26%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 1,283.18%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Adherex Technologies has higher revenue and earnings than Rani Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.40	-$9.74M	-$0.29	N/A
Rani Therapeutics	$1.63M	48.08	-$29.67M	-$0.41	N/A

Summary

Adherex Technologies beats Rani Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Lexeo Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Rani Therapeutics	$1.63M	48.08	-$29.67M	-$0.41	N/A

In the previous week, Rani Therapeutics had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.89 beat Rani Therapeutics' score of 0.69 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Very Positive
Rani Therapeutics	Positive

Lexeo Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 304.09%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,283.18%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lexeo Therapeutics' return on equity of -47.48% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Rani Therapeutics	N/A	-206.46%	-83.95%

Summary

Lexeo Therapeutics beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Abeona Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Rani Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 1,283.18%. Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 171.04%. Given Rani Therapeutics' higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Abeona Therapeutics had 10 more articles in the media than Rani Therapeutics. MarketBeat recorded 15 mentions for Abeona Therapeutics and 5 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.69 beat Abeona Therapeutics' score of 0.33 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics' return on equity of -53.98% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Abeona Therapeutics	N/A	-53.98%	-38.52%

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	48.08	-$29.67M	-$0.41	N/A
Abeona Therapeutics	$5.82M	68.64	$71.18M	$0.97	7.23

Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Summary

Abeona Therapeutics beats Rani Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, Palisade Bio had 22 more articles in the media than Rani Therapeutics. MarketBeat recorded 27 mentions for Palisade Bio and 5 mentions for Rani Therapeutics. Palisade Bio's average media sentiment score of 0.92 beat Rani Therapeutics' score of 0.69 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio currently has a consensus target price of $8.83, suggesting a potential upside of 367.37%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 1,283.18%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Palisade Bio's return on equity of -36.79% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Rani Therapeutics	N/A	-206.46%	-83.95%

Palisade Bio has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Palisade Bio has higher earnings, but lower revenue than Rani Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,312.26	-$16.78M	-$1.01	N/A
Rani Therapeutics	$1.63M	48.08	-$29.67M	-$0.41	N/A

Summary

Palisade Bio beats Rani Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$85.13M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.54	20.85	27.12	24.26
Price / Sales	48.08	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.86	8.49	10.89	6.29
Net Income	-$29.67M	$23.83M	$3.58B	$330.66M
7 Day Performance	-10.81%	-3.56%	-2.11%	-1.35%
1 Month Performance	-16.77%	6.31%	3.28%	-0.64%
1 Year Performance	-9.42%	48.30%	26.33%	19.08%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	1.9282 of 5 stars	$0.63 -7.9%	$8.75 +1,283.2%	-1.8%	$85.13M	$1.63M	N/A	110	News Coverage
ANL Adlai Nortye	1.9893 of 5 stars	$10.92 +15.1%	$24.25 +122.1%	+474.1%	$379.60M	$5M	N/A	127	News Coverage High Trading Volume
FENC Adherex Technologies	4.2704 of 5 stars	$10.69 -0.1%	$15.40 +44.1%	+22.4%	$373.29M	$44.64M	N/A	10	Gap Down
LXEO Lexeo Therapeutics	2.3779 of 5 stars	$4.60 -1.9%	$18.75 +307.6%	+3.8%	$368.27M	N/A	N/A	58	Gap Down
ABEO Abeona Therapeutics	3.4325 of 5 stars	$6.31 -1.4%	$19.00 +201.1%	+22.1%	$364.77M	$5.82M	6.51	90	Negative News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. ANL, FENC, LXEO, ABEO, and PALI

How does Rani Therapeutics compare to Adlai Nortye?

Summary

How does Rani Therapeutics compare to Adherex Technologies?

Summary

How does Rani Therapeutics compare to Lexeo Therapeutics?

Summary

How does Rani Therapeutics compare to Abeona Therapeutics?

Summary

How does Rani Therapeutics compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. ANL, FENC, LXEO, ABEO, and PALI

How does Rani Therapeutics compare to Adlai Nortye?

Do institutionals and insiders hold more shares of ANL or RANI?

Does the media favor ANL or RANI?

Which has higher valuation and earnings, ANL or RANI?

Do analysts recommend ANL or RANI?

Is ANL or RANI more profitable?

Which has more risk & volatility, ANL or RANI?

Summary

How does Rani Therapeutics compare to Adherex Technologies?

Which has more volatility and risk, FENC or RANI?

Does the media favor FENC or RANI?

Is FENC or RANI more profitable?

Do institutionals & insiders hold more shares of FENC or RANI?

Do analysts prefer FENC or RANI?

Which has preferable earnings and valuation, FENC or RANI?

Summary

How does Rani Therapeutics compare to Lexeo Therapeutics?

Which has more risk & volatility, LXEO or RANI?

Do insiders & institutionals hold more shares of LXEO or RANI?

Which has stronger valuation and earnings, LXEO or RANI?

Does the media favor LXEO or RANI?

Do analysts prefer LXEO or RANI?

Is LXEO or RANI more profitable?

Summary

How does Rani Therapeutics compare to Abeona Therapeutics?

Do analysts recommend RANI or ABEO?

Does the media refer more to RANI or ABEO?

Is RANI or ABEO more profitable?

Do insiders and institutionals hold more shares of RANI or ABEO?

Which has higher earnings and valuation, RANI or ABEO?

Which has more risk & volatility, RANI or ABEO?

Summary

How does Rani Therapeutics compare to Palisade Bio?

Does the media prefer PALI or RANI?

Do analysts rate PALI or RANI?

Is PALI or RANI more profitable?

Which has more volatility and risk, PALI or RANI?

Do institutionals & insiders believe in PALI or RANI?

Which has stronger earnings and valuation, PALI or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools